keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis quality of life

keyword
https://www.readbyqxmd.com/read/28213862/apremilast-a-review-in-psoriasis-and-psoriatic-arthritis
#1
Gillian M Keating
Apremilast (Otezla(®)) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque psoriasis in the phase 3 ESTEEM trials, as well as improving difficult-to-treat nail, scalp and palmoplantar psoriasis. Most patient-reported outcomes, including pruritus and the total Dermatology Life Quality Index, also improved to a significantly greater extent with apremilast than with placebo, with significant improvements in pruritus and skin discomfort/pain visual analogue scale scores seen as early as week 2 with apremilast...
February 18, 2017: Drugs
https://www.readbyqxmd.com/read/28196270/open-label-study-of-etanercept-treatment-in-patients-with-moderate-to-severe-plaque-psoriasis-who-lost-a-satisfactory-response-to-adalimumab
#2
J Bagel, S Tyring, K C Rice, D H Collier, G Kricorian, J Chung, J Iles, B S Stolshek, A Kaliyaperumal, K A Papp
BACKGROUND: Some plaque psoriasis patients experience secondary failure of tumour necrosis factor inhibitor therapy. OBJECTIVES: To evaluate efficacy, safety, and patient-reported outcomes (PROs) with etanercept in patients with secondary adalimumab failure. METHODS: This phase 4, open-label, single-arm, estimation study (NCT01543204) enrolled patients on adalimumab who had achieved static physician global assessment (sPGA) score 0/1 (clear/almost clear)...
February 14, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28192600/systematic-reviews-and-meta-analyses-on-psoriasis-role-of-funding-sources-conflict-of-interest-and-bibliometric-indices-as-predictors-of-methodological-quality
#3
F Gómez-García, J Ruano, M Aguilar-Luque, J Gay-Mimbrera, B Maestre-Lopez, J L Sanz-Cabanillas, P J Carmona-Fernández, M González-Padilla, A Vélez García-Nieto, B Isla-Tejera
BACKGROUND: The quality of systematic reviews (SRs) and meta-analyses about psoriasis, a chronic inflammatory skin disease that severely impairs quality of life and is associated with high costs, remains unknown. OBJECTIVES: To assess the methodological quality of SRs published on psoriasis. METHODS: After a comprehensive search in MEDLINE, EMBASE, and the Cochrane Database (PROSPERO:CDR4201604161), the quality was assessed by two raters using Assessment of Multiple Systematic Reviews (AMSTAR) tool...
February 13, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28182255/fatigue-in-psoriasis-a-controlled-study
#4
I M Skoie, I Dalen, T Ternowitz, G Jonsson, I Kvivik, K Norheim, R Omdal
BACKGROUND: Fatigue is associated with various chronic inflammatory diseases, but few studies have focused on its occurrence in psoriasis. OBJECTIVES: To describe fatigue prevalence and degree among patients with chronic plaque psoriasis compared with age- and gender-matched healthy subjects, and to examine how fatigue is influenced by essential clinical and demographic factors. METHODS: In 84 patients and 84 healthy subjects, fatigue severity was assessed using three different generic fatigue instruments: the fatigue Visual Analogue Scale (fVAS), the Fatigue Severity Scale (FSS), and the Short Form 36 (SF-36) vitality scale...
February 9, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28181669/characteristics-and-risk-profile-of-psoriasis-patients-included-in-the-czech-national-registry-biorep-and-a-comparison-with-other-registries
#5
Martina Kojanova, Jorga Fialova, Petra Cetkovska, Spyridon Gkalpakiotis, Jitka Jircikova, Tomas Dolezal, Petr Arenberger
BACKGROUND: BIOREP is a Czech registry of psoriatic patients on biological treatment in a clinical setting. We describe the characteristics of patients with psoriasis at the time of enrollment and present comparisons with published data from other national registries. METHODS: We analyzed the cohort of patients treated with biologics between May 2005 and May 2015. Demographic data, previous therapies, comorbidities, and severity of psoriasis were compared with data from other registries - DERMBIO, BIOBADADERM, BADBIR, and PSOBEST...
February 9, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28165828/certolizumab-pegol-for-the-treatment-of-psoriasis
#6
A Campanati, D Benfaremo, M M Luchetti, G Ganzetti, A Gabrielli, A Offidani
Psoriasis is a chronic immunomediated and inflammatory disease involving mainly skin and joints, often associated with several metabolic and non-metabolic comorbidities. TNF-alpha inhibitors have shown long-term efficacy and safety/tolerability in psoriasis, and preliminary data support the use of certolizumab pegol (CZP) as well. Areas covered: The authors review the pharmacological properties of CZP, as well as its safety data and efficacy profile. They also review the quality of life outcomes related to CZP in psoriasis...
February 6, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28156019/excessive-angiogenesis-associated-with-psoriasis-as-a-cause-for-cardiovascular-ischaemia
#7
Nina Malecic, Helen S Young
Psoriasis, a common disease affecting 2-3% of the UK population, produces significant impairment of quality of life and is an immense burden on sufferers and their families. Psoriasis is associated with significant cardiovascular co-morbidity and the metabolic syndrome. Angiogenesis, a relatively under-researched component of psoriasis, is a key factor in pathogenesis of psoriasis and also contributes to the development of atherosclerosis. Vascular endothelial growth factor (VEGF) is a well established mediator of pathological angiogenesis which is upregulated in psoriasis...
February 3, 2017: Experimental Dermatology
https://www.readbyqxmd.com/read/28150346/dermoscopic-features-of-nail-psoriasis-treated-with-biologics
#8
Yuki Hashimoto, Miki Uyama, Yuko Takada, Kenji Yoshida, Akira Ishiko
Although psoriatic nail lesions are small, they cause considerable discomfort for patients and adversely affect quality of life. Few studies have evaluated the dermoscopic features of psoriatic nails. The aim of this study was to clarify the dermoscopic features of nail psoriasis and identify those that reflect psoriatic activity. During biologic treatment of psoriasis, six patients with psoriatic nails twice underwent dermoscopic examination, with an interval of 17-42 weeks. We used the modified Nail Psoriasis Severity Index score and Psoriasis Area and Severity Index score to identify and assess dermoscopic features...
February 2, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28148701/need-for-improvement-in-current-treatment-of-psoriatic-arthritis-study-of-an-outpatient-clinic-population
#9
Brigitte Michelsen, Andreas P Diamantopoulos, Hege Kilander Høiberg, Dag Magnar Soldal, Arthur Kavanaugh, Glenn Haugeberg
OBJECTIVE: To explore the burden of skin, joint, and entheses manifestations in a representative psoriatic arthritis (PsA) outpatient cohort in the biologic treatment era. METHODS: This was a cross-sectional study of 141 PsA outpatients fulfilling the ClASsification for Psoriatic ARthritis (CASPAR) criteria and examined between January 2013 and May 2014. Selected disease activity measures were explored including Disease Activity index for PSoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Disease Activity Score (PASDAS), Disease Activity Score for 28 joints (DAS28), Simplified Disease Activity Index (SDAI), and Psoriasis Area Severity Index (PASI)...
February 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28148280/optimizing-adalimumab-treatment-in-psoriasis-with-concomitant-methotrexate-optimap-study-protocol-for-a-pragmatic-single-blinded-investigator-initiated-randomized-controlled-trial
#10
Celine Busard, Stef Menting, Sun-Jine van Bezooijen, Juul van den Reek, Barbara Hutten, Errol Prens, Elke de Jong, Martijn van Doorn, Phyllis Spuls
BACKGROUND: The introduction of anti-tumor necrosis factor medications has revolutionized the treatment of psoriasis with achievement of treatment goals (Psoriasis Area and Severity Index score 75, remission) that are not usually met with conventional systemics. Nevertheless, some patients continue to experience persistent disease activity or treatment failure over time. Strategies to optimize treatment outcomes include the use of concomitant methotrexate, which has demonstrated beneficial effects on pharmacokinetics and treatment efficacy in psoriasis and other inflammatory diseases...
February 2, 2017: Trials
https://www.readbyqxmd.com/read/28138946/ixekizumab-a-review-in-moderate-to-severe-plaque-psoriasis
#11
Yahiya Y Syed
Ixekizumab (Taltz(®)) is a subcutaneously administered, humanized anti-interleukin-17A monoclonal antibody indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (USA and EU) or phototherapy (USA). In the phase 3 UNCOVER trials in this patient population, ixekizumab was superior to placebo or etanercept in terms of the proportion of patients achieving a ≥75% reduction from baseline in the Psoriasis Area and Severity Index and in those achieving a static Physician Global Assessment score of 0 or 1, after 12 weeks of induction treatment...
February 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28132580/real-world-outcomes-in-2-646-psoriasis-patients-one-in-five-has-pasi-%C3%A2-10-and-or-dlqi-%C3%A2-10-under-ongoing-systemic-therapy
#12
J M Norlin, P S Calara, U Persson, M Schmitt-Egenolf
Background Although biologics introduced a new era in psoriasis care when available a decade ago, it is unclear to what extent the available systemic treatments treat patients adequately. Objective To analyse the clinical severity and quality of life of the psoriasis population in Sweden treated with systemics. Methods Data included 2,646 patients from the Swedish Registry for Systemic Treatment of Psoriasis. Average Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and EQ-5D were reported...
January 30, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28112799/efficacy-and-relapse-suppression-of-severe-plaque-psoriasis-by-oxymatrine-results-from-a-single-blinded-randomized-controlled-clinical-trial
#13
H Zhou, H-J Shi, J Yang, W-G Chen, L Xia, H-B Song, K-P Bo, W Ma
BACKGROUND: Current drugs in psoriasis treatment are associated with drawbacks such as rapid recrudescence, high costs and unwanted side effects. Oxymatrine has a long clinical use in the treatment of hepatitis and cancer in China. OBJECTIVE: To explore the efficacy and safety of oxymatrine injection in patients with severe plaque psoriasis. METHODS: Sixty-seven patients were randomly allocated to receive oxymatrine injections (0.6 g/d, 8weeks) or acitretin capsules (0...
January 23, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28103601/superiority-in-quality-of-life-improvement-of-biologics-over-conventional-systemic-drugs-in-a-swiss-real-life-psoriasis-registry
#14
Pierre Jungo, Julia-Tatjana Maul, Vahid Djamei, Stefanie von Felten, Antonios G A Kolios, Justine Czernielewsk, Nikhil Yawalkar, Olivia Odermatt, Emmanuel Laffitte, Mark Anliker, Markus Streit, Matthias Augustin, Curdin Conrad, Jürg Hafner, Wolf-Henning Boehncke, Michel Gilliet, Peter Itin, Lars E French, Alexander A Navarini, Peter Häusermann
BACKGROUND: Randomized controlled trials have shown the efficacy of systemic treatments in moderate-to-severe psoriasis. Clinical outcomes in psoriasis patients under real-world conditions are less well understood. OBJECTIVE: This study compared Psoriasis Area and Severity Index (PASI) and Dermatological Life Quality Index (DLQI) improvement in all psoriasis patients registered in the Swiss Dermatology Network for Targeted Therapies. We asked whether outcomes differed between 4 treatment strategies, namely biologic monotherapy versus conventional systemic monotherapy, versus combined biologic and conventional systemic drugs, and versus therapy adaptation (switching from one type to another)...
January 20, 2017: Dermatology: International Journal for Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/28087133/secukinumab-sustains-early-patient-reported-outcome-benefits-through-1%C3%A2-year-results-from-2-phase-iii-randomized-placebo-controlled-clinical-trials-comparing-secukinumab-with-etanercept
#15
Bruce Strober, Alice B Gottlieb, Bintu Sherif, Patrick Mollon, Isabelle Gilloteau, Lori McLeod, Todd Fox, Margaret Mordin, Ari Gnanasakthy, Charis Papavassilis, Mark G Lebwohl
BACKGROUND: Psoriasis is a chronic condition with negative impact on patients' quality of life that most often requires lifelong effective and safe treatment. OBJECTIVE: This analysis focused on the effect of secukinumab treatment on patient-reported health-related quality of life as assessed by the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis. METHODS: The proportion of subjects achieving DLQI score 0/1 response at week 24, time to DLQI score 0/1 response, and sustained DLQI score 0/1 response up to week 52 were compared between secukinumab and etanercept...
January 10, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28069297/lesions-on-the-back-of-hands-and-female-gender-predispose-to-stigmatization-in-patients-with-psoriasis
#16
Marlena Hawro, Marcus Maurer, Karsten Weller, Romuald Maleszka, Anna Zalewska-Janowska, Andrzej Kaszuba, Zofia Gerlicz-Kowalczuk, Tomasz Hawro
BACKGROUND: Psoriasis vulgaris is characterized by disfiguring and stigmatizing skin lesions. The links among lesions distribution, severity, and stigmatization remain unclear. OBJECTIVE: We sought to investigate if the involvement of visible and sensitive areas is linked to stigmatization. METHODS: In all, 115 patients with psoriasis vulgaris were assessed for disease severity, skin lesions distribution, itch, and stigmatization using the Feelings of Stigmatization Questionnaire...
January 6, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28064543/itolizumab-a-novel-anti-cd6-monoclonal-antibody-a-safe-and-efficacious-biologic-agent-for-management-of-psoriasis
#17
Sunil Dogra, Shraddha Uprety, Swaroop Hassan Suresh
Psoriasis, a chronic immune-mediated skin disorder is associated with significant physical, psychological, and quality of life impairments. Along with well-documented genetic and environmental factors, immunological factors also contribute to the pathogenesis of psoriasis. Among the immunological factors, CD6 - dependent T-cell proliferation to form Th1 and Th17 cells play a major role in the pathogenesis of psoriasis. Itolizumab is the first humanized IgG1 monoclonal antibody, which selectively targets CD6...
January 25, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28063525/the-impact-of-skin-diseases-on-quality-of-life-a-multicenter-study
#18
G Sanclemente, C Burgos, J Nova, F Hernández, C González, M I Reyes, N Córdoba, Á Arévalo, E Meléndez, J Colmenares, S Ariza, G Hernández
INTRODUCTION: To date, no formal study has been published regarding how Colombian patients with skin disorders could be affected according to their perception of disease. OBJECTIVE: To determine the impact in quality of life of skin diseases in a Colombian population. METHODS: This multicenter study included patients with skin disease from almost the whole country. Individuals >18 years old; of any gender; with any skin disease and who signed informed consent, were included...
January 4, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28057360/efficacy-and-safety-of-guselkumab-an-anti-interleukin-23-monoclonal-antibody-compared-with-adalimumab-for-the-continuous-treatment-of-patients-with-moderate-to-severe-psoriasis-results-from-the-phase-iii-double-blinded-placebo-and-active-comparator-controlled
#19
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Bruce Randazzo, Yasmine Wasfi, Yaung-Kaung Shen, Shu Li, Alexa B Kimball
BACKGROUND: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. OBJECTIVES: We sought to compare efficacy and safety of guselkumab with adalimumab and placebo in patients with psoriasis treated for 1 year. METHODS: Patients were randomized to guselkumab 100 mg (weeks 0 and 4, then every 8 weeks; n = 329); placebo→guselkumab (weeks 0, 4, and 12 then guselkumab at weeks 16 and 20, then every 8 weeks; n = 174); or adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47; n = 334)...
December 29, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28042711/the-impact-of-pasi-75-and-pasi-90-on-quality-of-life-in-moderate-to-severe-psoriasis-patients
#20
Michael Abrouk, M Nakamura, T H Zhu, B Farahnik, J Koo, T Bhutani
BACKGROUND: It is well known that psoriasis significantly impacts patients' quality of life (QoL). With the introduction of improved treatment modalities with biologic agents, more patients with moderate to severe psoriasis are able to achieve better results as measured by the Psoriasis Area and Severity Index (PASI). PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement. With newer biologic agents such as secukinumab, ixekizumab and brodalumab, patients are now capable of achieving PASI 90, introducing additional clinical decisions for physicians when considering treatment options...
January 18, 2017: Journal of Dermatological Treatment
keyword
keyword
65639
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"